Sintx Technologies Inc Stock Price, News & Analysis

Oxford Performance Materials (OPM) and SINTX Technologies (NASDAQ: SINT) announced a collaboration to develop a new poly-ether-ketone-ketone (PEKK) silicon nitride composite using OPM’s patented casting technology.

This partnership aims to enhance medical implants' biological response and reduce infection rates, potentially leading to faster recovery and improved patient outcomes.

Both companies emphasize their shared focus on nanotechnology and surface technologies, suggesting that this collaboration could yield innovative products in the biomedical field.

SINTX Technologies, Inc. (NASDAQ: SINT) has been included in the Russell Microcap Index, effective June 4, 2021. This inclusion recognizes SINTX's financial progress and its focus on silicon nitride applications in biomedical and commercial markets. The Russell Microcap Index serves as a benchmark for institutional investors to evaluate micro-cap stocks with market caps between $50 and $300 million. CEO Dr. Sonny Bal emphasized that this achievement reflects SINTX's innovation in developing products like wound care, spinal and dental implants, and consumer facemasks.

SINTX Technologies announced the launch of its new FleX SN product line, expanding from monolithic spinal implants to various silicon nitride technologies. These products target biomedical and antipathogenic applications, including wound care and spinal implants, building on a proven safety record from over 40,000 surgeries. The rebranding also includes a redesigned website and the submission of a trademark application for FleX SN. The company aims to broaden its market focus in biomedical and industrial sectors.

SINTX Technologies announced multiple U.S. and international patent applications focusing on the development of technologies utilizing silicon nitride for antipathogenic applications. Key patents include methods for the rapid inactivation of SARS-CoV-2, antipathogenic face masks, and systems for applying silicon nitride coatings. These innovations aim to enhance medical devices and address viral diseases, including COVID-19. SINTX underscores its commitment to leveraging silicon nitride's properties in improving medical device outcomes. The company operates an FDA registered and certified manufacturing facility.

SINTX Technologies, Inc. (NASDAQ: SINT) filed its 10-K for the year ended December 31, 2020. Despite COVID-19's impact, SINTX adapted its strategic plan, highlighting that its silicon nitride effectively inactivates the SARS-CoV-2 virus. Key investments were made in personnel, collaborations, and capital equipment. SINTX is focused on developing antipathogenic products and is optimistic about its future as it approaches its 25th year in business. A conference call is scheduled for March 30, 2021, to provide further updates.

SINTX Technologies has announced that its silicon nitride-embedded fabrics effectively inactivate the SARS-CoV-2 virus. Testing conducted by the University of Rochester demonstrated a 99.9% reduction in viral loads upon contact. These antiviral fabrics have potential applications in face masks, surgical gowns, and air filters. Unlike traditional masks that use metal additives, SINTX's fabrics are non-allergenic and non-toxic. The company is focused on scaling production to meet the global demand for antiviral protective equipment.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the FDA submission of a Master Access File (MAF) for its new Silicon Nitride – Polyetheretherketone (PEEK) composite material (SN-PEEK). This innovative material combines the advantages of both silicon nitride and PEEK, aiming to enhance spinal fusion implants. With proven benefits such as faster bone healing and infection resistance, SN-PEEK targets the spine and craniomaxillofacial markets. SINTX continues to innovate and seeks to expand its customer base through this latest development.

SINTX Technologies has entered into a worldwide exclusive licensing agreement with O2TODAY to develop consumer masks integrated with SINTX’s silicon nitride, aimed at inactivating pathogens and combating COVID-19. The agreement spans two years with options for extension and entails a licensing fee and royalties based on sales. Both companies believe this partnership will position O2TODAY as a market leader in innovative masks. The demand for respiratory protection is projected to grow, with shipments expected to exceed 10 billion units by 2025.

SINTX Technologies celebrates its 25th anniversary in 2021, marking over 35,000 spinal implantations and leadership in silicon nitride manufacturing. The company focuses on three growth areas: antipathogenic applications, industrial uses, and biomedical opportunities. The pandemic increased demand for protective equipment, with the reusable mask market expected to reach $7.08 billion by 2027. SINTX plans to launch a consumer mask with antiviral properties in collaboration with O2TODAY. Additionally, the company targets a $174 billion industrial market with its silicon nitride innovations.